U.S. Peptide Therapeutics Market - By Type (Branded, Generic), By Application (Metabolic, Cancer, Cardiovascular, Gastrointestinal), By Route of Administration (Parenteral, Oral), By Distribution Channel (Hospital, Retail)- Forecast 2023 to 2032

Description

List of Tables

U.S. Peptide Therapeutics Market is predicted to witness around 7% CAGR from 2023 to 2032, owing to increasing R&D activities. The quest for innovative and targeted treatment options has spurred investments in peptide-based drugs, with a focus on addressing complex medical conditions more effectively.

The rising prevalence of chronic diseases, such as diabetes and cardiovascular disorders, has driven the demand for advanced therapeutic solutions. According to the CDC's National Diabetes Statistics Report for 2022, cases of diabetes rose to an estimated 37.3 million in the U.S. The specificity and versatility of peptides make them well-suited for designing drugs with fewer side effects and enhanced efficacy. As the U.S. healthcare system fights with the challenges of chronic conditions, the adoption of peptide therapeutics is expected to grow.

The overall U.S. peptide therapeutics market is segmented on the basis of type, application, route of administration, manufacturer type, synthesis technology, and distribution channel.

Cancer segment is set to witness notable growth in the forecast period. Peptide therapeutics offer a unique advantage in cancer treatment due to their ability to specifically target cancer cells while minimizing harm to healthy tissues. The rising incidence of various cancers in the U.S. has prompted a surge in demand for innovative and targeted therapies. With advancements in peptide drug development and a deeper understanding of cancer biology, the U.S. healthcare sector is increasingly turning to peptide therapeutics for their potential in providing more effective and personalized treatment options for cancer patient.

Online pharmacies segment is anticipated to observe a significant CAGR during 2023 and 2032, driven by the evolving landscape of healthcare delivery. Online pharmacies offer a convenient and accessible platform for patients to procure peptide therapeutics, ensuring timely and seamless access to these specialized medications. The growing adoption of digital health solutions and the emphasis on telemedicine further catalyze the preference for online pharmacies, enabling patients to order and receive peptide therapeutics from the comfort of their homes.

Generic peptides segment is anticipated to gain momentum and grow at a strong CAGR through 2032, attributed to the accessibility and affordability for patients. This encourages widespread adoption and enhances patient compliance with peptide-based therapies, particularly in chronic conditions. Moreover, the generic peptides segment spurs competition, catalyzing advancements in manufacturing processes, formulation technologies, and quality assurance protocols.

Product Code: 7400

Chapter 1 Methodology & Scope

1.1 Market definitions
1.2 Base estimates and calculations
1.3 Forecast calculations
1.4 Data Validation
1.5 Data sources
- 1.5.1 Secondary
  - 1.5.1.1 Paid sources
  - 1.5.1.2 Public sources
- 1.5.2 Primary

Chapter 2 Executive Summary

2.1 U.S. Peptide therapeutics industry 360 degree synopsis, 2018 - 2032 (USD Billion)
- 2.1.1 Business trends
- 2.1.2 Type trends
- 2.1.3 Application trends
- 2.1.4 Route of administration trends
- 2.1.5 Manufacturer type trends
- 2.1.6 Synthesis technology trends
- 2.1.7 Distribution channel trends
- 2.1.8 Region trends

Chapter 3 U.S. Peptide Therapeutics Market Insights

3.1 Industry landscape, 2018 - 2032 (USD Billion)
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Increasing prevalence of cancer in the U.S.
  - 3.2.1.2 Rising incidences of metabolic disorders
  - 3.2.1.3 Increasing investments in R&D of novel drugs
  - 3.2.1.4 Technological advancement in peptide therapeutics
- 3.2.2 Industry pitfalls & challenges
  - 3.2.2.1 Stringent regulatory requirements for drug approval
  - 3.2.2.2 High cost for drug development
3.3 Growth potential analysis
- 3.3.1 By type
- 3.3.2 By application
- 3.3.3 By route of administration
- 3.3.4 By manufacturer type
- 3.3.5 By synthesis technology
- 3.3.6 By distribution channel
3.4 COVID-19 impact analysis
3.5 Clinical trial analysis
3.6 Technology analysis
3.7 Regulatory landscape
3.8 Porter's analysis
3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2022

4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Competitive positioning matrix, 2022
4.4 Strategic dashboard, 2022

Chapter 5 U.S. Peptide Therapeutics Market Estimates and Forecast, By Type, 2018-2032 (USD Billion)

5.1 Key trends, by type
5.2 Branded peptides
5.3 Generic peptides

Chapter 6 U.S. Peptide Therapeutics Market Estimates and Forecast, By Application, 2018-2032 (USD Billion)

6.1 Key trends, by application
6.2 Metabolic and endocrine disorders
6.3 Cancer
6.4 Cardiovascular disorders
6.5 Gastrointestinal disorders
6.6 Central nervous system disorders
6.7 Respiratory disorders
6.8 Pain management
6.9 Renal disorders
6.10 Dermatology
6.11 Other applications

Chapter 7 U.S. Peptide Therapeutics Market Estimates and Forecast, By Route of Administration, 2018-2032 (USD Billion)

7.1 Key trends, by route of administration
7.2 Parenteral
7.3 Oral
7.4 Other routes of administration

Chapter 8 U.S. Peptide Therapeutics Market Estimates and Forecast, By Manufacturer Type, 2018-2032 (USD Billion)

8.1 Key trends, by manufacturer type
8.2 In-house
8.3 Outsourced

Chapter 9 U.S. Peptide Therapeutics Market Estimates and Forecast, By Synthesis Technology, 2018-2032 (USD Billion)

9.1 Key trends, by synthesis technology
9.2 Liquid phase peptide synthesis (LPPS)
9.3 Solid phase peptide synthesis (SPPS)
9.4 Hybrid Technology

Chapter 10 U.S. Peptide Therapeutics Market Estimates and Forecast, By Distribution Channel, 2018-2032 (USD Billion)

10.1 Key trends, by distribution channel
10.2 Hospital pharmacies
10.3 Retail pharmacies
10.4 Online pharmacies

Chapter 11 Company Profiles

11.1 Pfizer, Inc
11.2 Amgen, Inc
11.3 Eli Lilly and Company
11.4 Sanofi SA
11.5 AstraZeneca
11.6 AbbVie, Inc.
11.7 GlaxoSmithKline plc
11.8 Baush Health Companies Inc.
11.9 Sun Pharmaceutical Industries Ltd.
11.10 Novo Nordisk